BELLUS Health enters 2016 with its lead programme KIACTATM for AA Amyloidosis approaching a pivotal moment. The Phase III confirmatory study is expected to reach completion early this year with top line data expected in the middle of the year. Given that the study is a doubled blinded placebo controlled trial, neither us nor BELLUS have any visibility on the outcome. However given the earlier study had demonstrated efficacy with the data having scored a p-value of 0.025 in relation to the end
11 Jan 2016
2016, a pivotal year for BELLUS Health
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
2016, a pivotal year for BELLUS Health
Blue Star Capital Plc (BLU:LON) | 0.0 0 0.0% | Mkt Cap: 1.66m
- Published:
11 Jan 2016 -
Author:
Derren Nathan -
Pages:
6
BELLUS Health enters 2016 with its lead programme KIACTATM for AA Amyloidosis approaching a pivotal moment. The Phase III confirmatory study is expected to reach completion early this year with top line data expected in the middle of the year. Given that the study is a doubled blinded placebo controlled trial, neither us nor BELLUS have any visibility on the outcome. However given the earlier study had demonstrated efficacy with the data having scored a p-value of 0.025 in relation to the end